Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antidepressant Adult Suicidality Labeling To Be Presented For Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will present potential labeling changes on antidepressant-related suicidality in adults at Dec. 13 PDAC meeting.

You may also be interested in...



FDA Should Add Age Modification To Antidepressant Suicidality Warning, Committee Says

Current “black box” warning on pediatric suicidality should be expanded to note that risk does not appear to extend beyond young adults, with possible protective effects in elderly populations.

FDA Should Add Age Modification To Antidepressant Suicidality Warning, Committee Says

Current “black box” warning on pediatric suicidality should be expanded to note that risk does not appear to extend beyond young adults, with possible protective effects in elderly populations.

Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow

The new patient Medication Guide is expected to reach pharmacies the week of March 7. The standardized MedGuides will be issued as tear-off pads for about a year until manufacturers implement unit-of-use packaging, which would allow the guide to be pre-packaged with every prescription.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel